Closed Loop Medicine
Closed Loop Medicine is a UK healthtech company developing AI-driven personalized drug-plus-software combination products, including WeDosify (GLP-1 dosing, US-launched September 2025), CLM-IN01 (insomnia), and CLM-HT01 (hypertension). It serves pharmaceutical companies, payors, and healthcare providers via licensing partnerships and a SaaS dosing platform.
- Company typePrivate
- Founded2017
- HeadquartersCambridge, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Closed Loop Medicine does
Closed Loop Medicine is a UK-based health technology company founded in 2017 that develops personalized drug-plus-software combination products, pairing pharmaceutical therapies with proprietary Software as a Medical Device (SaMD) to enable AI-driven adaptive dosing. The company's underlying platform combines machine learning with pharmacokinetic and pharmacodynamic (PK/PD) models to calculate individualized doses for each patient, with a closed-loop feedback architecture that returns patient response data to the platform for continuous refinement. The product portfolio includes WeDosify, a commercially launched GLP-1 titration platform deployed to US clinicians; CLM-IN01, a drug-device combination product for insomnia that has secured UKCA marking and CE designation; and CLM-HT01, a single-label combination product integrating SaMD with amlodipine for hypertension management.
The company operates a hybrid business model that monetizes its platform through two complementary streams: licensing and royalty-style arrangements with pharmaceutical partners for co-developed combination products (notably a strategic partnership with Teva UK announced in March 2024), and a recurring SaaS revenue stream from WeDosify deployments to healthcare providers, telehealth companies, and health systems, with initial US deployment at Amarillo Premier Research in Texas. Primary customers are pharmaceutical companies, payors, and healthcare providers, with the end beneficiary being patients with chronic conditions such as obesity, hypertension, and insomnia. The company's commercial and clinical positioning is supported by 4 granted patents and over 30 pending applications, ISO 27001:2022 certification, regulatory milestones across the UK and EU, recognition on TIME's 2025 World's Top HealthTech Companies list, and membership in the NVIDIA Inception Program.
Closed Loop Medicine is led by CEO Kate Woolland, who was appointed in May 2025 succeeding co-founder Hakim Yadi, with co-founder Dr Paul Goldsmith serving as Chief Medical & Innovation Officer and President. Luba Greenwood serves as Chair of the Board (appointed September 2024). The company is headquartered in Cambridge at Babraham Research Campus with a registered office in Altrincham, UK, and claims a global operating footprint spanning the UK, USA, Canada, Australia, Mexico, Israel, and Taiwan.
Closed Loop Medicine firmographics
Firmographics- Name
- Closed Loop Medicine
- Legal name
- Closed Loop Medicine Ltd
- Website
- https://closedloopmedicine.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Closed Loop Medicine is a UK healthtech company developing AI-driven personalized drug-plus-software combination products, including WeDosify (GLP-1 dosing, US-launched September 2025), CLM-IN01 (insomnia), and CLM-HT01 (hypertension). It serves pharmaceutical companies, payors, and healthcare providers via licensing partnerships and a SaaS dosing platform.
- Ownership category
- akta.pro rank
Closed Loop Medicine industry classification
Industry- Product category
- Digital Therapeutics Software
- NAICS
- Software Publishers (5132)
- SIC
- Services-Prepackaged Software (7372), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro industry
- Condition-specific Digital Therapeutics (DTx)Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)Therapeutic Companion Apps (Drug-Device-Digital Combination)Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
Keywords
Where Closed Loop Medicine is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
Closed Loop Medicine business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical Partnership Products: CLM partners with pharmaceutical companies to create patent-protected single prescription combination products. Each product is individually tailored to disease use settings and built using CLM's proprietary platform of intellectual property, regulatory expertise, and clinical evidence.
- SaaS Dosing Platform (WeDosify): WeDosify enables clinicians to personalize GLP-1 titration at scale. The platform is being deployed to healthcare providers, telehealth companies, and health systems to make informed titration decisions, representing a commercial software/platform revenue stream.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels6 records
Closed Loop Medicine product offering
Product offeringCore offering
Closed Loop Medicine (CLM) develops an AI-based adaptive dosing platform that combines drug therapy with digital care solutions to create patent-protected single-prescription combination drug-device products. The company delivers software-enabled precision dosing across therapy areas such as insomnia (CLM-IN01), hypertension (CLM-HT01), and GLP-1 obesity management (WeDosify), with clinical evidence drawn from 29 studies and 15,000+ patient profiles.
Product overview
Closed Loop Medicine is a health technology company that delivers personalized treatment solutions through a proprietary platform combining dose-optimized drug therapy with digital care. The company's portfolio includes WeDosify (a commercially available GLP-1 personalized dosing platform), CLM-IN01 (an insomnia drug-device combination product in regulatory development), and CLM-HT01 (a hypertension product integrating proprietary SaMD with amlodipine). The platform leverages AI-driven adaptive dosing algorithms, pharmacokinetic/pharmacodynamic modeling, and closed-loop feedback systems to enable genuine personalization at scale.
Differentiator
Problem solved
Functional benefit
Brands
- WeDosify: A GLP-1 dosing platform that enables clinicians to personalize GLP-1 titration at scale, delivering data-driven, adaptive dosing recommendations to improve GLP-1 adherence.
Quantifiable outcome
- 91% of GLP-1 patients would be more likely to stay on treatment with WeDosify support
- +2 more outcomes
Companies that use Closed Loop Medicine
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles3 records
Closed Loop Medicine technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature4 records
Closed Loop Medicine partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- Teva UKcoreStrategic partnership announced March 26, 2024 to advance development of personalised medicines. Teva UK and Closed Loop Medicine are collaborating to develop personalized treatment solutions combining drug therapy with digital care.
- Orient PharmaminorShown as a partner logo on CLM's website, indicating some form of collaboration or partnership relationship.
- Queen Mary University LondoncoreClinical partnership with Queen Mary University London for patient-centric healthcare innovation linking traditional therapeutics, medical devices and digital health. Dr David Collier serves as Clinical Director.
- uMedcorePartnership with uMed to combine their unique approach to clinical trial delivery with CLM's technology for decentralized clinical trials.
- CPI (Centre for Process Innovation)coreCPI collaborated with CLM on patient-centric healthcare innovation linking traditional therapeutics, medical devices and digital health. CPI provides core strengths in healthcare innovation.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
Closed Loop Medicine competitors and assessment
Company assessmentDirect peers
- Click Therapeutics: Click Therapeutics develops prescription digital therapeutics and drug-device-digital combination products (e.g., with Otsuka for depression). Closest direct peer given overlapping combination-product model and clinical SaaS delivery.
- Akili Interactive: Akili Interactive is a prescription digital therapeutic company (EndeavorRx) cleared by FDA as SaMD. Directly comparable as a DTx/SaMD publisher targeting clinician-prescribed software for chronic conditions.
- WellDoc: WellDoc develops BlueStar, an FDA-cleared digital therapeutic for diabetes management that combines medication and behavioral coaching. Closely aligned to CLM's drug + digital combination approach in chronic disease dosing.
- DoseMeRx: DoseMeRx is a precision dosing software platform that uses pharmacokinetic models and Bayesian algorithms to optimize medication dosing for individual patients. Highly comparable to CLM's AI-driven adaptive dosing approach.
- InsightRX: InsightRX provides precision dosing software leveraging PK/PD modeling and Bayesian forecasting for individualized drug dosing. Operates in the same personalized dosing category as CLM with comparable technology stack.
- Biofourmis: Biofourmis combines remote patient monitoring with AI-driven analytics for personalized therapy management in chronic disease. Comparable as a combination-product platform using sensor data + AI to optimize treatment.
- Voluntis (Aptar Pharma): Voluntis (now part of Aptar Pharma) develops companion digital therapeutics for oncology and diabetes medications. Closely aligned as a prescription SaMD paired with pharmaceutical products.
Emerging players
- Ro: Ro is a direct-to-patient telehealth platform that prescribes GLP-1 therapies and may bundle personalized dosing support. Emerging competitor in the GLP-1 dosing support space that CLM targets with WeDosify.
- Sidekick Health: Sidekick Health is a digital therapeutics company offering prescription digital therapeutics for chronic disease management. Comparable as a DTx platform pursuing pharma partnerships and combination-product positioning.
Broad incumbents
- Hims & Hers Health: Hims & Hers is a large telehealth platform that prescribes GLP-1 weight-loss drugs and is building proprietary dosing and care tools. A broad incumbent in personalized GLP-1 care delivery that could subsume or compete with WeDosify.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Closed Loop Medicine social profiles
Digital presenceClosed Loop Medicine financial estimates
Financial estimateRevenue estimate
Valuation estimate
Closed Loop Medicine leadership team
Management profileNumber of profiles
Profiles7 records
Closed Loop Medicine funding detail
Funding detailFunding overview
Funding rounds6 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Closed Loop Medicine M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Closed Loop Medicine
What does Closed Loop Medicine do?
Closed Loop Medicine (CLM) develops an AI-based adaptive dosing platform that combines drug therapy with digital care solutions to create patent-protected single-prescription combination drug-device products. The company delivers software-enabled precision dosing across therapy areas such as insomnia (CLM-IN01), hypertension (CLM-HT01), and GLP-1 obesity management (WeDosify), with clinical evidence drawn from 29 studies and 15,000+ patient profiles.
Is Closed Loop Medicine a public or private company?
Closed Loop Medicine is a private company. It is classified as venture growth investor backed and is currently operating.
When was Closed Loop Medicine founded?
Closed Loop Medicine was founded in 2017. It employs 1 to 10 people.
Where is Closed Loop Medicine based?
Closed Loop Medicine is headquartered in Cambridge, United Kingdom, in the Europe region.
How does Closed Loop Medicine make money?
Two revenue lines are on record. Pharmaceutical Partnership Products are the primary driver. The others are saaS Dosing Platform (WeDosify).
Who are Closed Loop Medicine's main competitors?
Direct peers on record are Click Therapeutics, Akili Interactive, WellDoc, DoseMeRx, InsightRX, Biofourmis and Voluntis (Aptar Pharma). Emerging players are Ro and Sidekick Health. Hims & Hers Health is listed as a broad incumbent.
Does Closed Loop Medicine have an API?
No public API is recorded for Closed Loop Medicine.
What industry is Closed Loop Medicine in?
Closed Loop Medicine's product category is Digital Therapeutics Software. Its primary akta.pro industry code is HLACANAA, Condition-specific Digital Therapeutics (DTx), with a secondary code of HLACANAH, Therapeutic Companion Apps (Drug-Device-Digital Combination). Its NAICS code is 5132 and its SIC code is 7372.